News - Page 65 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Post published:February 6, 2023
Post category:Press Release

Read more about the article Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Post published:February 3, 2023
Post category:Psychedelic Bulletin

Read more about the article Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

Post published:February 3, 2023
Post category:Press Release

Read more about the article <strong>Australia Recognises MDMA and Psilocybin as Medicines</strong>

Australia Recognises MDMA and Psilocybin as Medicines

Post published:February 3, 2023
Post category:Analysis

Read more about the article A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article Historical Insights on the Psychedelic Renaissance

Historical Insights on the Psychedelic Renaissance

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article A Spotlight on Psychedelic Research Methods

A Spotlight on Psychedelic Research Methods

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article Panel: Psychedelic Research Methods

Panel: Psychedelic Research Methods

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

Post published:February 2, 2023
Post category:Press Release

Read more about the article Silo Pharma Announces Expansion of Intellectual Property Portfolio

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Post published:February 2, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.